Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 12750540.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Platelet-rich thrombi are resistant to thrombolytics. Matrix metalloproteinases (MMPs) may be involved in platelet aggregation and contribute to thrombolysis failure in stroke patients. Plasma samples from 23 stroke patients who had received thrombolytics and from 47 healthy volunteers were examined for MMP-2 and MMP-9 by both enzyme-linked immunosorbent assays and zymography. The arteries were recanalized in 15 patients but not in the other 8. The MMP-9 plasma level was significantly higher in patients whose arteries were not recanalized. MMP-9 may be associated with the formation of a thrombolytics-resistant thrombus.
Medical subject headings
- Matrix Metalloproteinase 9
- Stroke
- Thrombolytic Therapy